Attached files
| file | filename |
|---|---|
| S-1 - S-1 - MiNK Therapeutics, Inc. | d111280ds1.htm |
| EX-10.17 - EX-10.17 - MiNK Therapeutics, Inc. | d111280dex1017.htm |
| EX-10.16 - EX-10.16 - MiNK Therapeutics, Inc. | d111280dex1016.htm |
| EX-10.15 - EX-10.15 - MiNK Therapeutics, Inc. | d111280dex1015.htm |
| EX-10.14 - EX-10.14 - MiNK Therapeutics, Inc. | d111280dex1014.htm |
| EX-10.13 - EX-10.13 - MiNK Therapeutics, Inc. | d111280dex1013.htm |
| EX-10.12 - EX-10.12 - MiNK Therapeutics, Inc. | d111280dex1012.htm |
| EX-10.11 - EX-10.11 - MiNK Therapeutics, Inc. | d111280dex1011.htm |
| EX-10.10 - EX-10.10 - MiNK Therapeutics, Inc. | d111280dex1010.htm |
| EX-10.4 - EX-10.4 - MiNK Therapeutics, Inc. | d111280dex104.htm |
| EX-10.3 - EX-10.3 - MiNK Therapeutics, Inc. | d111280dex103.htm |
| EX-10.2 - EX-10.2 - MiNK Therapeutics, Inc. | d111280dex102.htm |
| EX-10.1 - EX-10.1 - MiNK Therapeutics, Inc. | d111280dex101.htm |
| EX-3.3 - EX-3.3 - MiNK Therapeutics, Inc. | d111280dex33.htm |
| EX-3.1 - EX-3.1 - MiNK Therapeutics, Inc. | d111280dex31.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated March 17, 2021, with respect to the consolidated financial statements of MiNK Therapeutics, Inc., included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
September 13, 2021